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Proteins are crucial in virtually all cell activities. The vast majority of proteins interact with
other molecules to function properly. The investigation of biomolecular interactions calls for structural
and thermodynamic information acquired by a variety of experimental techniques and analytical
methods. This dissertation is mainly concentrated on two frequently used and powerful tools, Isothermal
Titration Calorimetry (ITC) and Nuclear Magnetic Resonance (NMR) spectroscopy, to investigate
protein interactions. p52 Shc, a well-studied cellular adaptor protein, is a positive regulator in the
mitogen-activated protein kinases pathway. We have confirmed that Shc interacts with both, integrin
tyrosine(s)-phosphorylated cytoplasmic tails and phosphotidylinositol lipids, through the same
Phospho-Tyrosine Binding (PTB) domain. The binding to phosphorylated peptides is enthalpy driven
and tighter, while Shc interactions with PtdIns are entropy driven and much weaker. Shc interactions
with PtdIns and β3-derived peptides are only weakly competitive with partially overlapping bindings
sites. We also observed thermodynamic indications for potential intramolecular interactions within Shc,
which could be perturbed by the binding to the phosphorylated receptor. BTN3A1, an immunoglobulin
superfamily member, was found recently to be critical in Vγ9Vδ2 T cell activation. We described a
phosphoantigen prodrug approach with great potency in Vγ9Vδ2 T cell stimulation. Our NMR and ITC
results revealed the intracellular binding of BTN3A1 to phosphoantigens. In addition, we have provided
biophysical evidence indicating the involvement of membrane proximal region in phosphoantigen
binding and potential structural changes within BTN3A1 intracellular region. By focusing on p52 Shc
and BTN3A1, I hope to demonstrate how a combination of structural and thermodynamic knowledge
can be utilized to answer many important questions in signaling transduction close to the cell membrane.
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Chapter 1 ITC in Protein Interaction Study

Principles of ITC

In biology, the answers to many important questions about biomolecular interactions
are closely related to a change in heat or enthalpy occurring during the process. ITC directly
measures the heat change absorbed from the surroundings for an endothermic process or
released to the surroundings for an exothermic process, which makes it an ideal technique to
study biomolecular interactions. ITC is a powerful tool to study biomolecular interactions by
depicting the complete thermodynamic profile including the binding affinity (Ka), the enthalpy
(ΔH) and entropy (ΔS) changes in a single experiment for interaction of interest (1).

ITC measures biochemical reactions at constant temperature. Modern ITC only
requires low quantity of samples and is capable of studying interactions with a dissociation
constant (Kd) in a range from nM to mM. Figure 1 is a schematic representation of NanoITC
calorimeter from TA Instruments. In the assembly of ITC reside the sample and reference cells.
When an ITC experiment is undergoing, the sample cell contains one of the reactant of the
reaction of interest and the reference cell contains a solution which has a similar heat capacity
of the buffer used for the sample in the sample cell. Prior to the start of the experiment, the
other reactant in exactly the same buffer is loaded into the titration syringe. The syringe is then
mounted onto the burette handle and inserted into the ITC instrument. During an experiment,
the burette handle rotates and spins the syringe to ensure fast and adequate mixing of the two
reactants. The stepwise injection of ITC is controlled by the software where the user can
specify the settings for the experiment such as temperature, injection volume and stirring
speed.
1
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Figure 1. A schematic representation of Nano ITC from ta instruments. Figure taken from
Nano Isothermal Titration Calorimeter (Nano ITC) Getting Started Guide, Revision A by TA
Instruments.
The mechanism of differential power compensation is utilized to achieve the high
sensitivity and short response time (2). Currents are applied to both cells during the experiment
to maintain them at constant temperature set by the user. The injection of one reactant in the
injection syringe to the other reactant induces heat released to the surrounding environment
2
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(an exothermic reaction) or absorbed from surrounding environment (an endothermic reaction).
The heat change in the sample cell causes the change in the current applied to the sample
cell resulting a voltage difference between the two cells. In this manner, the energetics of
isothermal biochemical reactions is converted to electrical signals.

Data Analysis of ITC

The determination of the parameters of the thermodynamic profiles of the reaction can
be derived from the basic equilibrium thermodynamics and Gibbs free energy equation (2, 3).
To demonstrate of the analysis of ITC data, we consider the simplest scenario, in which a
macromolecule (such as proteins and nucleic acids) binds to its ligand (such as small
molecules) with 1:1 stoichiometry. The association of the macromolecule with the ligand gives
us a reaction:
𝑀 + 𝐿 ⇌ 𝑀𝐿

(1)

where M is the macromolecule, L is the ligand and ML is the macromolecule-ligand complex.
For this reaction, the equilibrium association constant (Ka) is defined as:

𝐾𝑎 =

[𝑀𝐿]
1
=
[𝑀][𝐿] 𝐾𝑑

(2)

where [ML], [M], [L] are the concentrations of free ML, M and L, respectively, and Kd is the
dissociation constant of the equilibrium. Due to the mass balance of the system, we have the
following relations among the free, bound and total concentrations for M and L:
[𝑀]𝐵 = [𝐿]𝐵 = [𝑀𝐿]

(3)

[𝑀] 𝑇 = [𝑀] + [𝑀𝐿]

(4)

[𝐿] 𝑇 = [𝐿] + [𝑀𝐿]

(5)

3
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where [M]B and [L]B are the concentrations of bound M and L, respectively, and [M]T and [L]T
are the concentrations of total M and L, respectively. The Gibbs free energy can be derived
from the following two equations:
Δ𝐺 = −𝑅𝑇𝑙𝑛𝐾𝑎

(6)

Δ𝐺 = Δ𝐻 − 𝑇Δ𝑆

(7)

ITC directly measures the heat (qi) released or absorbed from the reaction triggered by
the ith titration of L into M in the reaction cell. Meanwhile, qi is directly proportional to the
characteristic enthalpy change (ΔH) of the reaction and increase in [L]B:
𝑞𝑖 = 𝑣 × Δ𝐻 × Δ[𝐿]𝑖

(8)

where v is the volume of the reaction cell and ΔLi is the increase in [L]B thanks to the ith injection
of L. In our simplest case where the macromolecule has only one binding site, the Equation (8)
becomes:

𝑞𝑖 = 𝑣 × ΔΗ × [𝑀] 𝑇 × (

𝐾𝑎 [𝐿]𝑖
𝐾𝑎 [𝐿]𝑖−1
−
)
1 + 𝐾𝑎 [𝐿]𝑖 1 + 𝐾𝑎 [𝐿]𝑖−1

(9)

where [L]i is the concentration of free ligand after the ith injection. However, the Equation (8) is
still not in its implementable form and it needs to be rewritten in terms of the total ligand
concentration. The total cumulative heat, Q, is directly proportional to [L]B (hence [ML] due to
Equation (3)) as in:
𝑄 = 𝑣 × Δ𝐻 × ∑ Δ[𝐿]𝑖 = 𝑣 × Δ𝐻 × [𝐿]𝐵 = 𝑣 × Δ𝐻 × [𝑀𝐿]

(10)

which gives us the following equation:
[𝑀𝐿]
𝑄
=
[𝑀] 𝑇 𝑣 × Δ𝐻 × [𝑀] 𝑇

(11)

From Equations (2) to (5), we also obtain:
4
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[𝑀𝐿]
𝐾𝑎 [𝐿]
=
[𝑀] 𝑇 1 + 𝐾𝑎 [𝐿]
[𝑀] 𝑇 = [𝑀𝐿] + [𝑀] = [𝑀𝐿] +

(12)
[𝑀𝐿]
𝐾𝑎 [𝐿]

(13)

Thus, we have a quadratic equation for [ML]:
[𝑀𝐿]2 + [𝑀𝐿] (−[𝑀] 𝑇 − [𝐿] 𝑇 −

1
) + [𝑀] 𝑇 [𝐿] 𝑇 = 0
𝐾𝑎

(14)

The only real root for Equation (13) can solved and substituted in to Equations (5), (10) and
(11). Eventually, we establish the implementable form to determine Ka, ΔH from the non-linear
least-squares analysis of the dependent, Q, versus the known independent variable, usually
[L]T/[M]T. The precise relation is:

𝑄=

(1 + [𝑀]𝐾𝑎 + 𝐾𝑎 [𝐿] 𝑇 ) − [(1 + [𝑀]𝐾𝑎 + 𝐾𝑎 [𝐿] 𝑇 )2 − 4[𝑀]𝐾𝑎2 [𝐿] 𝑇 ]1/2
2𝐾𝑎
𝑣 × Δ𝐻

(15)

Figure 2 demonstrates the parameters calculation from the data acquired by ITC. The
upper panel shows the raw data collected in an ITC experiment. Each peak is the heat change
induced by an injection. The peaks pointing different directions (up or down) indicates the
reaction being endothermic or exothermic. The lower panel represents the integration of the
row data with the fitted curve for an exothermic protein-ligand interaction with 1:1 stoichiometry.
Each data point on the plot of the lower panel is calculated from the area under peak for the
corresponding peak in the row data. On the X-axis, the cumulative total ligand-protein ratios
are calculated after each injection.

5
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Figure 2. An example of itc raw data and processed data with a fitted independent model
with 1:1 stoichiometry
After the fitting, the important thermodynamic parameters are reflected on the sigmoidal
curve (Figure 2). The distance between the two horizontal asymptotes of the curve represents
the enthalpy change, ΔH, of the reaction. The stoichiometry of the reaction is obtained by
determining where the midpoint is on the X-axis for the sigmoidal curve. The slope at this point

6
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specifies the binding affinity, Ka, of the reaction. In addition, Equations (6) and (7) enable us to
obtain the Gibbs free energy change, ΔG, and entropy change, ΔS, for the reaction of interest.

Practical Considerations in an ITC Experiment

ITC is popular in biophysical studies due to its simplicity and capability in determining
a complete thermodynamic profile for the interaction of interest in short time (4). ITC
instruments directly measure the energy associated with a chemical reaction in a stepwise
fashion (1). The reaction cell contains one of the reactants, usually macromolecules such as
proteins and nucleic acids. The other reactant of the reaction, usually with better stability and
solubility at higher concentrations, such as small molecules, is loaded into the injection syringe
and its injection is controlled by the ITC software.
ITC is a highly sensitive technique to study biochemical reactions and it is easy to use.
ITC experiments do not need any special modifications for the reactants and can be done
using spectroscopically silent samples in a wide range biologically relevant conditions (such
as pH, buffer and temperature). However, there are precautions a researcher needs to pay
attention to in order to obtain the optimal results.
For simplicity, we focus the association of a protein with its ligand of a small molecule
with 1:1 stoichiometry (Table 1). An optimal binding curve from ITC should contain the two
“platform” phases in the beginning and in the end of the curve while the transition phase is not
too steep or flat to obtain an accurate estimate of the slope at the midpoint as shown in Figure
3A.
Kd (μM)

ΔH (kJ/mol)

TΔS (kJ/mol)

stoichiometry

1

50

15.75

1

Table 1. Thermodynamic parameters for the simulated reaction
7
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Figure 3. Simulated itc data to find the optimal concentrations for the reactants
ITC is able to study biochemical reactions with a Kd in a range from nanomolar to
millimolar. However, there are still limitations. We can determine if a reaction is suitable for
ITC based on a parameter known as:
𝑐 = 𝐾𝑎 × [𝑀]

(16)

where Ka is the reciprocal of Kd and [M] is the concentration of macromolecule sample. An
initial value of Kd can be obtained from other techniques or a test ITC run in order to calculate
the value for c as in Equation 16. Modern ITC instruments are capable of directly measure
reactions with 10 < c < 1000 (Table 2). A c value lower than 10 gives a transition too flat to

8
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determine ΔH (Figure 3D). On the other hand, a c value greater than 1000 gives a transition
too steep, which leaves few points to accurately determine the slope at the midpoint (Figure
3E).

Experiment

[L] (μM)

[M] (μM)

c

[L]/[M]

Comment

A

150

25

25

6

Optimal

B

300

25

25

12

Saturated too fast

C

75

25

25

3

Saturation not achieved

D

15

2.5

2.5

6

c < 10

E

7500

1250

1250

6

c > 1000

Table 2. Concentrations used to generated simulated ITC data in Figure 3
In order to achieve the optimal binding curve, the reactant is usually 5-10 times more
concentrated than the other reactant in the sample cell (Figure 3, Table 2). Thus it is
reasonable to have the reactant, which has better solubility and stability under the experiment
condition, in the injection syringe. In case of our protein-ligand interaction example, it is a
common practice to prepare the ligand of small molecule at a higher concentration. The exact
ratio can be determined in simulation based on the volumes of the injection syringe and the
sample cell of a specific ITC model available.

9
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Chapter 2 NMR spectroscopy in Protein Interaction Study

Overview of NMR Spectroscopy

In biology, in order to understand how macromolecules (such as proteins and nucleic
acids) function, related structural information is essential. ITC is popular in biophysical studies
due to its simplicity and capability in determining a complete thermodynamic profile for
interaction of interest in short time (4). NMR spectroscopy, on the other hand, focuses on
structural information at the atomic level and is particularly valuable in protein dynamics studies.
Along with X-ray crystallography, NMR spectroscopy has become one of the two primary
techniques to solve three-dimensional structures of macromolecules including protein and
nucleic acids. In addition, it is also widely used to reveal the structural details of biomolecular
binding events such as protein-protein and protein-ligand interactions (5). Unlike X-ray
crystallography, NMR can monitor biomolecular interactions in solution at a near-physiological
condition.
Over the past few decades, the range of biological system suitable for NMR has been
remarkably expanded by the improvement in instrumentation, application of multidimensional
techniques and other methodological advances (6-8). NMR has been employed successfully
in structural determination of large-sized proteins (9) and membrane proteins (10). In the
dissertation, we mainly utilized two-dimensional NMR experiments, especially 1H-15N HSQC,
to study a variety of protein interactions and protein conformational changes upon ligand
binding.
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Principles of NMR Spectroscopy

The fundamental principle of NMR spectroscopy comes from the behavior of nuclei in
an external magnetic field. In the scope of our discussion here, we will focus on spin-1/2 nuclei
(including 1H, 13C and 15N). When an external magnetic field is applied to the nuclei, the nuclei
are distributed into higher and lower spin energy states. As described by the Boltzmann
distribution, there are only slightly more nuclei at lower energy state than higher energy state.
The energy difference between the two states, ΔE, is proportional to the strength of the external
magnetic field:
Δ𝐸 =

𝜇𝐵0
𝐼

(1)

where µ is the magnetic moment of the nucleus, B0 is the strength of applied external magnetic
field and I is the spin number of the nucleus (I = ½ for spin-1/2 nuclei). The magnetic moment,
µ, is positively related to the gyromagnetic ratio, γ, of the nucleus:

𝜇=

𝛾𝐼ℎ
2𝜋

(2)

where h is Planck constant.

Figure 4. Spin-1/2 nuclei in an external magnetic field. E represents the energy difference
between the two states and B0 is the strength of applied external magnetic field. Figure taken
from https://www2.chemistry.msu.edu/faculty/reusch/virttxtjml/spectrpy/nmr/nmr1.htm.
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When a nucleus is irradiated with radio frequency (RF) energy corresponding exactly
to the difference between the two energy states, nuclei at lower energy state absorb the energy
and are excited to the higher energy state resulting in NMR signals. The process of nuclei in
excitation return to the lower energy state is called relaxation in NMR. Relaxation also
describes how NMR signals deteriorate with time. The rate of relaxation can be used to define
how fast NMR signals become gradually weaker and broader and is vital in NMR spectroscopy.
There are two major relaxation processes: spin-lattice relaxation and spin-spin
relaxation. The spin-lattice relaxation is a process in which the nuclei emits energy to the
surrounding environment. T1 is often used to describe how long this process takes place and
is also the decay constant for the recovery of the longitudinal component (parallel to the
direction of B0 in Figure 5A) of the nuclear spin magnetization in excitation to the equilibrium
state. The spin-spin relaxation, on the other hand, is a process in which a nucleus interacts
with neighboring nuclei resulting in a decaying transverse nuclear spin magnetization due to
decoherence. The over-population of the excited state does not change in the spin-spin, or T2,
relaxation but the life time of the NMR signal from the transverse nuclear magnetization
(perpendicular to the direction of B0 in Figure 5B) becomes shorter. T1 relaxation is responsible
for the weakening and T2 is accountable for the broadening in NMR signals.
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Figure 5. T1 (spin-lattice) and T2 (spin-spin) relaxation (from blue to red). The Z-axis
represent the direction of B0. Figure modified from http://www-mrsrl.stanford.edu/~brian/bloch/.

Chemical Shifts in Protein NMR

The magnetic field at the nucleus is not equal to the applied external magnetic field due
to the nuclear shielding phenomena in which the electrons circulating around a nucleus creates
a secondary induced magnetic field. The induced magnetic field can oppose or align with the
external magnetic field causing a shift in the resonant frequency of a nucleus in a magnetic
field. After standardized by a reference, the chemical shift is defined as the relative resonant
frequency of a nucleus to the reference, which is independent of the strength of the external
magnetic field. In chemistry, chemical shifts are particularly helpful for structural determination
of small molecules.
In protein NMR, the backbone chemical shift assignments of

Cα,

13

Cβ,

13

13

C’,

N, 1Hα

15

and 1HN, as the first step in NMR structure determination process, can often be carried out
rapidly using moderate amount of sample. NMR chemical shifts, which are highly sensitive to
local structure, provides us with a broad range of structural factors including secondary
13
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structure, backbone and sidechain conformations and hydrogen bonding (11, 12). Thus, the
structural information encoded in chemical shift values should not be overlooked. In addition,
assorted protein dynamics studies require the prerequisite assignment of the chemical shifts
of backbone atoms. Notably, the exploration of the structure-chemical shift relationship has
been an active area and advancing rapidly. Direct utilization of backbone chemical shifts has
been shown to considerably improve the accuracy of the protein structures predicted from
homology/de novo modeling (13, 14). The capability of predicting high-quality protein
structures based on sequence homology and experimental NMR backbone chemical shift data
may represent a new direction for high-throughput NMR structure determination.

1H-15N

HSQC 2D Experiments

Among a variety of 2D heteronuclear NMR experiments (such HSQC and HMQC), 1H15

N HSQC is one of the most frequently used experiments in protein NMR (15). 1H-15N HSQC

experiments require 15N protein samples which are easy to produce and inexpensive compared
to

13

C labeled samples. Due to its better sensitivity, 1H-15N HSQC can be acquired in a short

period of time compared other multidimensional NMR experiments. 1H-15N HSQC correlates
the chemical shifts of the amide protons with the covalently bound

15

N amide nitrogens. In a

1

H-15N HSQC spectrum, each peak represents a bonded amide N-H pair with the

corresponding coordinates of the chemical shifts of the 1H and 15N. 1H-15N HSQC spectra can
be considered as the “finger-print” of the protein and are often collected first in the structural
determination process. The perturbation of chemical shifts in 1H-15N HSQC spectra can serve
as indicators for protein interactions. With the assignment of the spectrum, the perturbations
can be mapped upon the protein structure hence reveal the binding sites on the protein for its
ligand.
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Chapter 3 p52 Shc in Signaling

Shc Family

Shc was one of the first characterized cellular adaptor proteins and a key node in the
activation of MAPK signaling in response to growth factors, cytokines, antigens, integrin
activation and mechanical force (16-18). By complexing with a wide range of membrane
receptors, the Shc family stands as a first point of signaling network convergence in cell by
transducing signals from the cell surface to DNA in the nucleus. The Shc family has significant
physiological impact on animal development and maintenance (16). Furthermore, Shc has
been implicated to be crucial in cancers including prostate (19) and breast cancer (20-22), and
many other diseases (16). In human, the p52 isoform of Shc is ubiquitously expressed but also
highly regulated. Given its pivotal role in cell regulation, vast in vivo and in vitro studies have
been conducted in last two decades to decode the molecular mechanism of Shc in signaling.
However, a number of new findings lend strong evidence to notion that Shc plays a versatile
role in signal transduction including its inhibitory function in the MAPK signaling pathway (23)
and its positive regulation in the PI3K/AKT pathway (21, 24).
All members in the Shc family share a PTB-CH1-SH2 core architecture (Figure 6) and
are only distinguished by the difference in the length of their N-termini (16). In addition to its Cterminal SH2 domain, which is capable of binding tyrosine-phosphorylated targets, the Nterminal PTB domain was later characterized as a novel type of protein motif, which also binds
tyrosine-phosphorylated targets. Nonetheless, the two independent pTyr-docking domains,
PTB and SH2, recognize pTyr-containing sequences in two distinct manners. In case of the
PTB domain, the classical pTyr-binding site defines its specificity by selectively recognizing
the residues N-terminal to the pTyr residue (25), especially the sequence Φ-X-Asn-Pro-X-pTyr
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(Φ represents a hydrophobic residue); however, the specificity of SH2 is primarily determined
by residues C-terminal to the pTyr residue and prefers the sequence pTyr-Φ-X-Ile/Leu/Met
(26). Between the PTB and SH2 lies the highly flexible proline-rich CH1 region, which, once
phosphorylated at Y239/240 (27, 28) and Y317 (29, 30), offers the recognition motifs to the
downstream partner Grb2 to activate the MAPK pathway.

Figure 6. The protein architecture of p52 Shc. The yellow circles represent the tyrosines in
the CH1 region which undergo phosphorylation during the activation of Shc.

Shc in MAPK Pathway

The canonical view of Shc in the MAPK pathway is in linking stimulated receptors to
the activation of the downstream MAPK pathway (17). Generally, activated and tyrosinephosphorylated receptors recruit Shc through the PTB or SH2 domain of Shc. Interestingly,
the PTB domain, not SH2, is predominantly chosen by membrane receptors. Therefore so far
most in vivo and in vitro studies on Shc have focused on the PTB domain. Recruitment of Shc
to the activated receptors leads to phosphorylation in the CH1 region of Shc at Y239/240 and Y317
(27, 29). The phosphorylated tyrosine residues form two consensus binding motifs to
downstream adaptor protein Grb2. The formation of Shc-Grb2 complex leads to the activation
of Ras/MAPK and results in the phosphorylation of the terminal kinase Erk by Mek in the MAPK
pathway (16). In summary, traditionally defined as a positive mediator in pTyr-based signaling
pathways, Shc links stimulated membrane receptors (via PTB or SH2) to downstream signaling
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pathways (via CH1) activating Ras/MAPK. Though remarkable progress has been achieved in
our knowledge of Shc, many intriguing studies have led to a perception that Shc functions in
more ways than its role as a positive regulator in the MAPK pathway.

Shc in PI3K/AKT Pathway

By using a combination of in vivo and in vitro methods, Suen and co-workers
demonstrated that the PTB domain of Shc exhibits direct binding to the N-terminal lobe of Erk
kinase in non-stimulated cells (23). This interaction was suggested to have inhibitory effects
on Erk’s activity by restraining its nuclear translocation and impeding Erk-dependent gene
transcription. The binary Shc-Erk complex is disrupted once the CH1 region of Shc is tyrosinephosphorylated resulting in a potential conformational change within Shc. The release of Erk
from the Shc-Erk complex makes Erk susceptible for activation. Those exciting findings
strongly indicate a new inhibitory role of Shc in the MAPK pathway. Combined with its orthodox
positive regulatory function, a dual role of Shc in MAPK is suggested: in non-stimulated cells,
Shc suppresses the activation of MAPK by coupling with Erk and restricting its kinase activity;
in the presence of extracellular stimuli, Shc is recruited by various receptors and
phosphorylated in the CH1 region, ultimately leading to the activation of MAPK. Integrins, a
major class of transmembrane receptors which mediate cell-cell and cell-extracellular matrix
interactions (31), are among the broad range of receptors recruiting Shc via the PTB domain
(32, 33). Previously, we have identified a classical binding site and a novel binding site on PTB
for β3CT (34). Surprisingly, the suggested binding site on PTB for Erk overlaps with the novel
binding site for pY747 of β3CT (Figure 7). It would be very intriguing to investigate how Erk and
β3CT compete over the same binding site on the Shc PTB domain.
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Figure 7. Illustration of Erk and β3CT competing over the same binding site on Shc PTB.
The structure of the PTB domain (light yellow) in complex with bi-β3 (green) is generated from
PDB entry 2L1C. The amino acids suggested to directly bind Erk are colored in blue (23). The
region resides in the long loop which contributes to form the novel binding site for pY747 in β3CT.
As Shc has been defined as a major signaling axis that activates the MAPK signaling
pathways, several studies have shown its importance in the PI3K/AKT pathway (21, 24). The
PI3K/AKT pathway makes significant contributions to many aspects of cell growth and survival
(35). Class 1A PI3Ks (hereafter referred to as PI3Ks) comprise a regulatory/inhibitory subunit
p85 and a catalytic subunit p110. When activated, PI3Ks, via its p85 subunit, are recruited to
the plasma membrane by various receptors and produce phosphatidylinositol-(3,4,5)trisphosphate (PIP3) as a secondary messenger (35). AKT has been identified as the major
positive downstream mediator of the PI3K signaling pathway. Gu and co-workers performed
in vitro studies demonstrating Shc’s positive function in the activation of PI3K/AKT pathway
(24). They found that by forming the complex of Shc-Grb2-Gab2, CH1-phosphoyrlated Shc, as
a part of the complex, is linked to the p85 subunit of PI3K and eventually promotes the
activation of downstream AKT. This new mechanism of Shc was believed to be crucial in the
activation of the PI3K/AKT mediated by receptors lacking direct binding sites for the p85
subunit of PI3K. 14-3-3 proteins, a class of ubiquitously expressed phosphoserine/threonine
binding modules and known to bind a wide range of diverse signaling proteins, serve as
positive regulators of Akt downstream signaling (36). Recently, the Tyr179 of 14-3-3 was found
18
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to be phosphorylated in a cytokine-dependent manner and a direct interaction occurs between
the SH2 domain of Shc and pY179 of 14-3-3ζ (37). Moreover, over-expression of the ζ isoform
of the 14-3-3 protein family was found to be associated with increased AKT phosphorylation in
human breast tumors (38). Later on, by employing transgenic mice expressing Shc with nonfunctional SH2 domain, Ursini-Siegel and co-workers showed the SH2-dependent Shc
signaling in the activation of PI3K/AKT is crucial for breast tumor outgrowth and survival (21).
Thus, it is highly likely that Shc, via its CH1 and/or SH2, plays a significant role in the PI3K/AKT
pathway.
We have used a phosphopeptide encompassing pY179 of 14-3-3ζ (p-1433ζ:
174

FSVFY(pY)EILNSPEK186) in our ITC studies to confirm the presence of a direct interaction

between isolated Shc SH2 domain and pY179-14-3-3ζ. The thermodynamic parameters of the
interactions revealed a binding affinity in the low μM range and an enthalpy and entropyfavorable process (Figure 8 and Table 3).
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Figure 8. ITC results showing a direct interaction between Shc SH2 domain and p-1433ζ
phosphopeptide at 37 °C
Kd (µM)

ΔH (kJ/mol)

-TΔS (kJ/mol)

ΔG (kJ/mol)

6.28 ± 0.209

-6.45 ± 0.531

23.5 ± 4.56

-30.0 ± 4.03

Table 3. Summary of the thermodynamic data for Shc SH2 interaction with p-1433ζ
phosphopeptide at 37 °C
In summary, as a convergence point for many signaling pathways, Shc has been
believed to fulfill an up-regulatory function in the MAPK pathway. A growing number of
independent studies have suggested the biological significance of Shc is not limited to this. In
the MAPK pathway, Shc may also act to prohibit undesirable activation in the non-stimulated
cell by complexing with Erk kinase (23). Outside the MAPK pathway, Shc seems to be crucial
in the up-regulation of the PI3K/AKT pathway involving membrane receptors lacking a binding
site for p85 subunit of PI3K (21, 24). Increasing studies have shown the necessity to better
understand the diversity of Shc’s functionality in signaling.
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Chapter 4 Phospho-Tyrosine(s) versus Phosphatidylinositol Binding in Shc
Mediated Integrin Signaling

Based on Lin, X. and Vinogradova, O., 2015. Phospho-Tyrosine (s) vs. Phosphatidylinositol
Binding in Shc Mediated Integrin Signaling. American journal of molecular biology, 5(2), p.17.

Introduction

Integrin mediated signaling events control numerous developmental, physiological and
pathological processes in multicellular organisms. Although significant progress has been
achieved in the understanding of integrin activation (39, 40), the early intracellular events
following the integrin mediated extracellular matrix engagement are not well characterized
structurally. To illuminate the potential mechanisms of integrin selectivity in the recognition of
proximal effectors at different stages of cell spreading, we have studied the effect of
phosphorylation on the conformation, membrane insertion, and target binding capability of the
cytoplasmic tail of the major platelet integrin αIIbβ3 (41, 42). Here we extend this investigation
by presenting our new work on deciphering the role that PtdIns lipids might share with
phosphotyrosine(s) in integrin signaling.
Amongst the number of potential chemical modifications correlated with the activated
state of integrin receptor, it is the tyrosine(s) phosphorylation of the cytoplasmic tail that has
been proven crucial for the outside-in signaling events (43-47). Shc p52 isoform, more
specifically, its PTB domain, has been identified as the primary signaling partner for the
tyrosine(s) phosphorylated β3CT (47, 48). This cytoplasmic adaptor protein, known to mediate
MAPK signaling pathway (49), needs to be localized at the cytosolic face of the plasma
membrane in order to be readily recruited by a number of different receptors (50). Two of Shc’s
three distinct domains, PTB and SH2, have the potential to bind phospholipids and, thus, might
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assist Shc translocation to the lipid bilayer (51, 52). Though only the PTB, and not the SH2
domain, is shown to interact with specific PtdIns (53). The purpose of the work presented here
is to compare molecular details of the interaction between Shc and integrin to the binding mode
between Shc and phospholipids.
Since their discovery about two decades ago, PTB domains have been identified and
structurally characterized within numerous multi-domain proteins. The ways they interact with
their targets are strikingly versatile. The phosphorylated tyrosine is not always required for the
high affinity interactions, and, in some cases, the binding motif might not even contain the
tyrosine residue at all (54). PTB domains in general are also famous for the significant variance
in their ligand binding affinities, ranging from 0.1 to 100 μM (55). Shc PTB domain in particular
exhibits a wide range of affinities to various tyrosine-phosphorylated binding partners. The
tightest interaction, with a Kd of 0.19 µM, was measured by ITC for the nerve growth factor
receptor TrkA derived peptide (56), correcting the originally over-estimated Kd value of 53 nM
(by Scatchard analysis of Surface Plasmon Resonance data) (57). Upon the structure
determination of Shc PTB in complex with a β3 integrin derived bi-phosphorylated peptide, biβ3 (41), we have found that the C-terminal phosphotyrosine (pY759) of β3CT occupies the
classical PTB binding pocket. The other phosphotyrosine (pY747) containing motif fits nicely
into the grove formed between the second helix and the unusually long flexible loop (~24
residues) connecting the second beta strand with the second helix in PTB fold. In this
interaction, a negatively charged phosphate group of pY747 forms a salt-bridge with a positively
charged side chain of Shc R104. This second binding site is in close proximity to the Shc residue
R112, which is situated at the beginning of the PTB domain second beta strand. This R112, along
with two lysines, K116 and K139, which also contain positively charged side chains, has been
proposed earlier to mediate Shc PTB-phospholipids interaction (58). In addition, Zhou and coworkers have originally found that Shc PTB domain has higher specificities to acidic PtdIns,
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particulalry PtdIns(4)P1 and PtdIns(4,5)P2 (Figure 9), over the other lipids that they have tested
(53). Furthermore, the binding of the full length Shc, enclosing the SH2 domain, to Ins (1,4,5)P3
(Figure 9), representing the polar head group of PtdIns(4,5)P2, has been reported to be much
tighter than the binding of the isolated Shc PTB domain alone to PtdIns(4,5)P2 (59). Therefore,
in order to investigate whether β3 integrin/phospholipids binding sites on Shc PTB surface
indeed overlap, what the thermodynamic profiles of these interactions are, and how β 3CT
derived phosphopeptides might affect Shc’s ability to localize itself to the lipid bilayer we have
initiated a through biophysical characterization of the above system. Here we present our data,
acquired by ITC and NMR experiments, which allowed us to visualize PtdIns mediated Shc
association with the lipid bilayer and how tyrosine(s)-phosphorylated integrin cytoplasmic tail
could later replace PtdIns from their binding site on Shc surface. Out data also suggests that
the interaction between the cytoplasmic tails of activated integrin receptors and Shc may result
in the rearrangement/separation of Shc internal domains.
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Figure 9. Structures of PtdIns molecules used in the study

Shc Interaction with Phosphatidylinositols Tested Using Ins(1,4,5)P3

We started our investigation by studying Shc binding to Ins (1,4,5)P3 using ITC. We
were greatly surprised that we were not able to reproduce the data reported by George and
co-workers, who have reported a tight dissociation constant (Kd of 0.7 µM) for the full length
Shc (59). No binding was found under any conditions tested (to have a better control on all
possible variables, we have purchased Ins (1,4,5)P3 from the same supplier (Cayman Chemical)
as reported in the paper. The conditions we tested include: i) Shc PTB domain at 12°C and
25°C in several different buffers (including exactly the same as the one described by George,
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which is 50 mM Tris, pH 8.0, 200 mM NaCl, 1 mM Dithiothreitol); ii) Shc full length at 12°C
and 25°C; and iii) Shc SH2 domain at 12°C and 25°C (typical raw titration data is shown as
an example in the Figure 10a-c). In the attempt to interpret our negative findings, we
hypothesized that the heat of the reaction was too small, actually below the detection range
of our Nano ITC calorimeter. Thus, we turned to NMR as the method of choice due to its
endogenous ability to capture the interactions with minimal or no enthalpy changes. In this
case, we performed

15

N-HSQC chemical shifts mapping experiments by titrating the

unlabeled Ins (1,4,5)P3 into the

15

N-labled Shc PTB domain. Under the conditions tested (see

Materials and Methods for details), we only observed minimal chemical shift perturbations
for the handful of residues in the

15

N-HSQC spectra even at the maximum of lipid to protein

ratio (15 to 1, Figure 10d). Uncertain about these findings, we decided to choose different
lipid mimetics for further investigation.
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Figure 10. ITC and NMR studies on the interaction of Shc PTB domain and Ins(1,4,5)P3. (a)
Ins(1,4,5)P3 does not show to bind to Shc PTB domain at 25 °C in ITC. (b) Ins(1,4,5)P3 does not
show to bind to full length Shc at 25 °C in ITC. (c) Ins(1,4,5)P3 does not show to bind to SH2
domain at 25 °C in ITC. (d) 15N-HSQC titration of PTB domain by Ins(1,4,5)P3. The effect from
Ins(1,4,5)P3 only show up at a high PTB-to-Ins(1,4,5)P3 ratio (1:15) and is less pronounced
compared to PtdIns(4,5)P2.
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Shc Interaction with Phosphatidylinositols Analysed by ITC Using PtdIns(4)P1
and PtdIns(4,5)P2

With minimal success observing Shc interaction with Ins(1,4,5)P3, representing
exclusively the polar head-groups of phosphatidylinositols, we wondered whether the aliphatic
chains of the lipids were necessary for the measurability of the binding by ITC and NMR. Long
lipid chains are not exactly soluble in aqueous solution. Thus, to perform the binding studies
described below, we restricted the length of aliphatic chains to six carbons in dihexanoyl, or
eight in dioctonoyl phosphatidylinositol derivatives and concentrated on PTB domain of Shc,
previously shown to interact specifically with PtdIns(4)P1 and PtdIns(4,5)P2 (53). Binding affinities
for the apo PTB domain, originally examined in the unilamellar liposomes centrifugation assay,
were reported to be 52 μM for PtdIns(4)P1 and 140 μM for PtdIns(4,5)P2. Binding affinity of the
PTB domain complexed with TrkA peptide was reported to be even weaker, with a Kd of roughly
450 μM for both lipids.
First, we employed ITC to determine the binding affinities of the PTB domain to three
different phosphatidylinositol containing soluble probes (see the Materials and Methods
section for details). We measured a Kd of 95 µM and 125 µM for PtdIns(4)P1 and PtdIns(4,5)P2
respectively (titration curves and isotherms are presented in Figure 11a and Figure 11b). ITC
was not able to detect the binding PtdIns(5)P1 (titration curve is shown Figure 12), thus
confirming the specificity of interaction reported by Zhou and coworkers. The ITC
measurements demonstrated similar binding affinity for PtdIns(4,5)P2 as compared to the affinity
previously determined by centrifugation assay data analysis, though PtdIns(4)P1 appeared to
bind about two times weaker than reported before (53). Small amounts of heat are consumed
upon binding (in addition to the relatively large heat of solvation), demonstrating endothermic
interactions at 25°C that are driven predominantly by entropy. Considering these data, it is not
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entirely surprising that we were only able to observe minimal Shc PTB binding with Ins(1,4,5)P3
alone in ITC. The complete thermodynamic analysis of the above interactions is presented in
the Table 4.

Figure 11. ITC and NMR studies on the interaction of Shc PTB domain and PtdIns. (a)
PtdIns(4)P1 and (b) PtdIns(4,5)P2 binding to Shc PTB domain at 25 °C.
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Figure 12. PtdIns(5)P1 does not show to bind to Shc PTB domain at 25 °C in ITC
Ligand

Kd (µM)

ΔH (kJ/mol)

-TΔS (kJ/mol)

ΔG (kJ/mol)

PtdIns(4)P1

95.00

1.51

-24.46

-22.95

PtdIns(4,5)P2

125.1

1.94

-24.21

-22.27

PtdIns(5)P1

No binding

Table 4. ITC data for Shc PTB domain binding to PtdIns at 25°C

PtdIns Binding Sites on Apo Shc PTB Surface Partially Overlap with Integrin
Binding Sites

To find out the molecular details of these weak Shc-PtdIns interactions, we next
employed NMR and performed

15

N-HSQC chemical shifts mapping experiments which are
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especially useful to define weak binding (60). Two non-labeled PtdIns derivatives, PtdIns(4)P1
and PtdIns(4,5)P2, demonstrated to interact with Shc PTB by ITC experiments, were titrated into
the samples containing 15N-labeled apo PTB domain. Chemical shift perturbations, associated
with the probes binding, were monitored. Overall, the observed shifts in Shc PTB resonance
frequencies were small. However, they were concentration dependent, reproducible, and
similar among the two PtdIns tested. Furthermore, the same residues were affected as the
ones in Ins(1,4,5)P3 titration described above (Figure 10d), but the shifts were more pronounced
in case of PtdIns(4,5)P2, even at 5 to 1 lipid to protein ratio as compared of 15 to 1 ratio for
Ins(1,4,5)P3. The close-ups of

15

N-HSQC spectra of PTB in the presence of PtdIns(4,5)P2,

exemplifying the most shifted resonances, are shown in Figure 13. These chemical shifts
perturbations occur at three major binding regions. The first one, represented by the residues
Q148, S149 and A168, overlaps with the classical phospho-tyrosine binding pocket of the proteinpeptide binary complex. However, the canonical PTB fold cannot be formed without the
stabilizing hydrophobic residue (pY-5) of the target peptide. Thus, in apo PTB domain
Ins(1,4,5)P3 could only establish intermediate dynamic contacts with the amine functional groups
of R67 or Q148 side chains. The second binding site, including the residues L63, Q76 and S107, is
formed at the interface of the second helix, the loop connecting the first beta strand with the
second helix and the beginning of the second beta strand. This second PtdIns binding site is
distinct from the second novel phospho-tyrosine binding site we previously described for Shc
PTB-bi-β3 complex (41), although it includes several overlapping residues. The third PtdIns
binding site is restricted to a single but the most perturbed residue of the spectra, F30, which is
located within the unstructured Shc PTB N-terminus. The chemical shift perturbations in

15

N-

HSQC spectrum of apo Shc PTB upon PtdIns(4,5)P2 titration, plotted against the residue number,
are presented in Figure 13. The inset demonstrates affected residues mapped onto PTB
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surface, which is colored according to the absolute value of the corresponding chemical shift
perturbations.

Figure 13. 15N-HSQC spectra showing chemical shifts perturbations in a classical PTB
binding pocket, the second binding site and F30. Chemical shifts perturbations upon
PtdIns(4,5)P2 binding to apo Shc PTB domain inset with surface mapping of PTB generated from
PDB entry 1OY2. The surface is colored acorrding to the corresponding chemical shift
perturbations, Delta (ppm), from yellow (smallest) to red (largest) and light gray indicating
missing assignments. Delta (ppm) refers to the combined HN and N chemical shift changes,
obtained from the equation: Δδ(HN,N) = ((ΔδHN2 + 0.2(ΔδN)2)1/2, where Δδ = δbound – δfree.
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Story of Integrin Interactions with the Shc - PTB Domain versus Full Length Shc

Two of the Shc three distinct domains, PTB and SH2, have the potential to bind
phospho-tyrosines and/or phospholipids. However, in all the experiments performed we did
not observe any indications of Shc SH2 domain interaction with either PtdIns or β3 integrin
derived tyrosine(s)-phosphorylated peptides. Thus, we focused our investigation on studying
the PTB domain alone and comparing it to the full length Shc in order to understand the
thermodynamic forces driving the interactions. We started with a bi-β3 peptide, which was used
previously for the structural characterization of the Shc PTB/integrin binary complex (41). We
found that at 25 °C Kd of this interaction was 5.1 μM (ΔG = -30.17 kJ/mol) and it was
predominantly driven by enthalpy (ΔH = -22.98 kJ/mol). A representative calorimetric isotherm
and the corresponding titration curve, depicted in Figure 14a, demonstrate that the interaction
is exothermic at 25 °C, releasing the heat upon peptide binding with a stoichiometry of about
1. The driving force of this complex formation is very different from the one defined for the TrkA
peptide (enthalpy vs. entropy), and it shows a higher specificity, even though the binding affinity
is about twenty five times weaker (5.14 µM vs. 0.19 µM). We have speculated that the
secondary binding site for pY747 within the complex might be responsible, at least in parts, for
the difference. To find out whether this was the case, we ran ITC experiments for the smaller
c-β3 peptide containing only one terminal pY759 (Figure 14b). Our reasoning appeared to be
wrong. The shorter (13 vs. 27 residues) mono-phosphorylated peptide had an even higher
binding affinity with the Kd of 0.34 µM (ΔG = -36.86 kJ/mol) and an even larger favorable
enthalpy term (ΔH = -25.41 kJ/mol). The thermodynamic analysis of the above interactions is
presented in Table 5.
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Figure 14. (a) Bi-β3 peptide and (b) c-β3 peptide binding to Shc PTB domain at 25 °C.
Shc construct

Ligand

T (°C)

Kd (µM)

ΔH
(kJ/mol)

25

5.14

-22.98

bi-β3

ΔCp
-TΔS
(kJ/mol∙K) (kJ/mol)

ΔG
(kJ/mol)

-7.191

-30.17

-17.75

-29.27

-11.45

-36.86

-8.446

-32.63

-2.784

-31.60

-12.55

-28.82

-26.13

-33.53

-12.17

-33.20

-0.88
12

4.32

-11.52

25

0.35

-25.41

PTB Domain
c-β3

-0.09
12

1.05

-24.18

25

2.84

-28.82

bi-β3

-0.96
12

5.21

-16.27

25

1.33

-7.40

Full Length
c-β3

1.04
12

0.82

-21.03

Table 5. Summary of the thermodynamic data for Shc interaction with β3 integrin derived
mono- and bi-tyrosine-phosphorylated peptides acquired from the ITC measurements
at two temperature points using full length Shc and PTB domain constructs.
Next, we decided to find out how the Shc solvent-accessible surface area was affected
during the reaction. This was accomplished by investigating the change in constant pressure
heat capacity (ΔCp). ΔCp is given by the slope of the linear regression analysis of ΔH plotted
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vs. temperature (Equation 17), and it is often independent of temperature within the narrow
physiological range (reviewed in (61)). Thus, two temperature points, 12 °C and 25 °C, would
provide an estimate for the slope. For binding reactions, negative ΔCp is expected to
demonstrate the reduction in protein surface area in contact with the solvent. The larger and
more negative values reflect a larger surface area buried upon complex formation. Through
this correlation, structural information of the macromolecular complex could be inferred from
the thermodynamic parameters. As expected, the longer bi-β3 peptide in complex with Shc
PTB domain demonstrated a more negative ΔCp of about -0.88 kJ/mol∙K as compared to the
shorter c-β3 peptide represented by ΔCp of -0.09 kJ/mol∙K (see Table 5 for details). This
correlates well with the larger solvent-accessible surface area buried upon binding of the longer
peptide. As we already established that the Shc SH2 domain does not bind to either of the
above peptides, we decided to confirm that the full length Shc behaves similarly to PTB domain
alone. To our great surprise that was not the case. We found that while bi-β3 peptide in complex
with full length Shc showed quite similar ΔCp of about -0.96 kJ/mol∙K, binding of c-β3 peptide
resulted in a positive ΔCp of about 1.04 kJ/mol∙K. That means that upon complex formation
with c-β3 peptide more of the Shc solvent-accessible surface area was exposed. The only
reasonable explanation of this phenomenon that we can imagine is the unraveling of the
intramolecular interactions between the domains within Shc itself.

Δ𝐶𝑝 =

𝜕ΔH
𝜕𝑇

(17)

PtdIns Only Weakly Compete with β3-Peptides for Interaction with Shc

We were also curious about the relation between binding sites for PtdIns and β 3peptides (bi-β3 and c-β3) on Shc PTB surface. If these sites do not overlap, the presence of β3peptide should not interfere with the interaction between PTB and PtdIns; thus, PtdIns should
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cause concentration-dependent perturbations in the spectra of the PTB-β3-peptides complex.
In case of a competitive binding between PtdIns and β3-peptides to PTB, since Shc’s affinity
to bi-β3 and c-β3 is much higher in comparison to its affinity to phospholipids, it is reasonable
to speculate that integrin tyrosine(s)-phosphorylated CTs can easily replace PtdIns from the
partially overlapping binding sites on the Shc surface. We have proved the latter scenario by
using NMR. First, we prepared protein samples of the PTB domain with PtdIns added at
protein-PtdIns ratios of 1:0, 1:3, 1:5 and 1:15. Then bi-β3 or c-β3 was added to the sample at a
1:2 protein-to-peptide ratio and

15

N-HSQC experiments were performed. The

15

N-HSQC

spectra of both Shc PTB-bi-β3 and Shc PTB-c-β3 complexes in the absence and the presence
of PtdIns(4)P1, PtdIns(4,5)P2 or Ins(1,4,5)P3 overlap perfectly (an example of the overlapping
spectra is presented in Figure 15). Therefore, we have confirmed that the binary interfaces
between Shc PTB and phosphopeptides remained the same in the presence of phospholipids
added in excess. Also, bound peptides did not allow PtdIns to occupy their partially accessible
(according to the chemical shifts mapping experiments summarized in Figure 13) potential
binding sites on the surface of PTB domain. The remaining question was whether PtdIns could
affect the thermodynamic profiles of Shc interaction with phosphorylated peptides. To test this,
we investigated the binding of full length Shc and Shc PTB domain with bi-β3 and c-β3 peptides
in the presence of Ins(1,4,5)P3 by ITC. As expected, our data indicate that the protein samples
over-saturated by Ins(1,4,5)P3 at 3 to 1 lipid to protein ratio were not much different in Shc binding
to either of the peptides. The most noticeable difference, observed in a single case, was the
perturbation in the thermodynamic profile of the full-length Shc titrated by bi-β3, where the
unfavorable 3 kJ/mol change in enthalpy was almost compensated by the favorable change in
entropy term, resulting in a slight reduction of Kd value (see Table 6). The impact from Ins(1,4,5)P3
on the peptide interaction with Shc was also evidenced in this case by the appearance of small
negative peaks ahead the dominating positive peaks in the titration curve (presented in Figure
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16), when the reaction was close to saturation. In the absence of the lipid mimetic, the small
negative peaks were not present. This phenomenon is quite specific, as no similar patterns
were witnessed in any other ITC experiments performed for studying Shc- bi-β3/c-β3 binding.
Lastly, to complete the investigation and to confirm the inability of PtdIns to replace the
phosphopeptides, we performed titrations of PtdIns into Shc PTB complexed with
phosphorylated peptides (bi-β3 or c-β3, 2:1 peptide to protein ratio). We then monitored
potential changes in HSQC spectra by NMR or in calorimetric isotherms by ITC. As expected,
no indications of binding were observed by either method.

Figure 15. 15N-HSQC spectra of Shc PTB pre-satured by Ins(1,4,5)P3 (at protein-PtdIns
ratios of 1:0, 1:3, 1:5 and 1:15) with bi-β3 added (at a 1:2 protein-to-peptide ratio). The
lack of difference in the overlaid spectra indicates that integrin tyrosine(s)-phosphorylated β3
integrin CTs can easily replace PtdIns from the overlapping binding sites on the Shc surface.
Shc
construct

Ligand

Kd (µM)

ΔH (kJ/mol)

-TΔS
(kJ/mol)

ΔG (kJ/mol)
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bi-β3

4.32

-11.52

-17.75

-29.27

bi-β3 + Ins(1,4,5)P3

3.65

-12.37

-17.30

-29.66

c-β3

1.05

-24.18

-8.45

-32.63

c-β3 + Ins(1,4,5)P3

1.12

-23.62

-8.84

-32.46

bi-β3

5.21

-16.27

-12.55

-28.82

bi-β3 + Ins(1,4,5)P3

4.38

-13.87

-15.37

-29.23

c-β3

0.82

-21.03

-12.17

-33.20

c-β3 + Ins(1,4,5)P3

0.87

-21.11

-11.96

-33.07

PTB Domain

Full Length

Table 6. Summary of the thermodynamic data for Shc interaction with β3 integrin derived
mono- and bi-tyrosine-phosphorylated peptides acquired from the ITC measurements
at 12°C in the presence and the absence of Ins(1,4,5)P3
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Figure 16. Full length Shc binding to bi-β3 in the absence (upper) and presence (lower)
of Ins(1,4,5)P3 at 25 °C

Discussion

Scaffold adaptor protein Shc can be recruited through numerous receptors, including
integrins, growth factors, antigens, cytokines, G-protein-coupled, and hormone receptors (50).
Interactions of this cytoplasmic protein with specific phospholipids have been proposed as a
mechanism for its translocation to the membrane (51, 52). Despite vast structural, functional,
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and biophysical data characterizing Shc involvement in signal transduction from different
receptors, its interactions with integrins or specific phospholipids are much less studied or
understood. We have analyzed Shc binding to tyrosine(s) phosphorylated peptides derived
from β3 integrin and PtdIns using ITC and solution NMR methods. Through these studies we
have found that PtdIns only weakly compete with phosphorylated integrin cytoplasmic tail for
Shc PTB binding. This conclusion is based on several observations. First, Shc interactions
with phosphopeptides are characterized by several orders of magnitude higher affinity than
binding to PtdIns. Second, Shc interaction with peptides is enthalpy driven in contrast to the
entropy driven interaction with phospholipids. Third, the overall conformational rearrangement
of Shc PTB domain upon interaction with the phosphopeptides is coupled with the replacement
of PtdIns from their binding sites on Shc surface. Lastly, PtdIns cannot replace
phosphotyrosines from their PTB binding sites and the unoccupied surface is not sufficient to
stabilize Shc PTB interaction with phospholipids.
The most interesting finding in this study comes from the thermodynamic analysis of
mono- and bi-phosphorylated peptides binding to Shc PTB domain vs. the full length Shc.
Although there are not many differences in the ΔCp of bi-β3 binding, characterized by expected
negative values of about 0.9 kJ/mol∙K for solvent-accessible surface area buried in both cases,
there is a striking difference in ΔCp of c-β3 binding. While for PTB domain alone ΔCp is
expectedly reduced (shorter peptide) but still negative, full length Shc binding is characterized
by the positive ΔCp value of about 1.0 kJ/mol∙K. This suggests exposure of the originally buried
solvent-accessible surface area, which is larger than the surface of interaction with monophosphorylated peptide, and this is only possible if the interactions among PTB, CH1 and SH2
domains within Shc have been disrupted. One of the potential rearrangement schemes for Shc
domains upon binding different peptides is proposed in Figure 17. In this scenario, Shc is
recruited to the membrane by the interaction of its PTB domain with PtdIns. While binding of
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the bi-phosphorylated integrin releases PTB domain from the membrane, β3CT-PTB complex
may still provide the surface area necessary for intra-molecular interaction with other domains
of Shc. Contrarily, binding of mono-phosphorylated peptide might result in conformational
rearrangements leading to a more “extended” Shc structure as PTB domain detaches from the
lipid bilayer. As Shc is known to be a positive regulator in the MAPK pathway, the recruitment
of Shc to the activated receptors leads to phosphorylation in the CH1 region at Y239/240 and Y317.
The phosphorylated tyrosine residues form two consensus binding motifs to the downstream
adaptor protein Grb2 and the formation of Shc-Grb2 complex eventually leads to the activation
of the MAPK pathway. We have established previously that integrin cytoplasmic tails are
capable of accommodating different structural features depending upon their binding partner
and/or the phosphorylation state (39, 41, 42, 62). Our new data suggests that they can also
cause variable conformational rearrangements in their targets, as Shc seems to adapt different
conformations when binds mono/bi-phosphorylated β3 cytoplasmic tail. The plausible biological
significance of the dexterity in the conformation of Shc may contribute to differential
phosphorylation in the CH1 region. Although both Y239/240 and Y317 are capable of serving as
the binding site for Grb2, the biological outcomes emanating from the two phosphorylation
sites can be significantly different (63). Deciphering this remarkable dexterity should definitely
aid in better understanding of crucial bidirectional information flow through these distinct
receptors.
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Figure 17. A model for Shc-mediated integrin signaling at the cytosolic face of the
plasma membrane. The cytoplasmic tails of integrin αIIb and β3 are shown in red and blue,
respectively. The PTB domain and SH2 domain of Shc are shown in cyan and gray,
respectively. The molecules of PtdIns(4,5)P2 and phosphotyrosines are colored acorrding to
heteroatoms. This descriptive model was generated in Chimera (64) by using PDB entries:
1OY2,
1TCE,
1S4X,
2KNC,
1SHC,
2LJE,
2L1C,
and
Phosphorylethanolamine/Phosphocholine lipid membrane (65). (a) Shc is recruited to the
membrane by the interaction of its PTB domain with PtdIns, integrin heterodimer is shown in
latent state; (b) binding to the activated mono-phosphorylated β3CT via PTB results in the
conformational rearrangements leading to a more “extended” full length Shc; (c) binding to the
activated bi-phosphorylated β3CT releases PTB domain from the membrane, though β3CTPTB complex may still provide the surface area necessary for the interaction with the other
internal Shc domains.
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To conclude, we have: i) confirmed that Shc interacts with both, integrin tyrosine(s)phosphorylated cytoplasmic tails and PtdIns lipids, through the same PTB domain (another
potential hub, SH2 domain, is not involved in these interactions); ii) found that phosphorylated
peptides binding is enthalpy driven and tighter, while Shc interactions with PtdIns are entropy
driven and are much weaker; iii) determined that Shc interactions with PtdIns and β 3-derived
peptides are only weakly competitive and are characterized by partially overlapping bindings
sites; iv) observed thermodynamic indications for potential intramolecular interactions within
Shc, which could be perturbed by the binding to the phosphorylated receptor; and v) proposed
a model for Shc-mediated integrin signaling through its recruitment to the lipid bilayer, which
paves the foundation for the future experiments.

Research Design and Methods

Materials and Reagents
Ins(1,4,5)P3 was purchased from Sigma and Cayman Chemical. (dihexanoyl- or
dioctonoyl-) PtdIns(4)P1, PtdIns(5)P1 and PtdIns(4,5)P2 were purchased from Cayman Chemical
(Figure
736

9).

Phosphopeptides

derived

from

β3CT

(bi-β3:

RAKWDTANNPL(pY)KEATSTFTNIT(pY)RGT762 and c-β3: 750ATSTFTNIT(pY)RGT762) were

synthesized by NEO-Peptide.

Cloning and Protein Purification
The Shc PTB domain (17-207) containing the pET15b vector was transformed into
Rosetta (DE3) cell line to pursue optimal expression levels (41). SH2 domain (380-473) was
cloned into NdeI and XhoI sites in pET21b vector and then transformed into a BL21 (DE3) cell
line. The vector of pET28a-full length Shc (1-473), generously provided by Dr. Ladbury
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(University of Texas MD Anderson Cancer Center, TX), was expressed in BL21 (DE3) cell line
as well. Typically, 10 ml overnight culture was used to inoculate 1 liter LB broth. Cells were
grown at 37 °C until OD600 reached 0.6. At this point the culture was cooled to room
temperature and then the overnight overexpression was induced by 1 mM isopropyl-β-Dthiogalactopyranoside. Harvested cells were kept at -20 °C for future purification or
resuspended in lysis buffer supplemented with protease inhibitors. Cells were further lysed by
french press and the cell debris was removed by centrifugation at 18,000 rpm at 4 °C. The Nterminal His-tag fused PTB domain and full length Shc, and the C-terminal His-tag fused SH2
domain were first purified under native conditions with Ni-NTA resin (QIAGEN) using the
standard protocol followed by a buffer exchange to 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM
β-mercaptoethanol in a Superdex-75 column (GE Healthcare) where all three recombinant
proteins showed a proper folding in monomeric state (Figure 18). The overexpression of the
target protein and the purified protein were confirmed by SDS-PAGE and the bands of the
expected mass were observed. The determination of protein concentration by UV
measurement was consistent with Bradford assay.
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Figure 18. Chromatograms from Size-exclusion chromatography in a Superdex-75
column and SDS-PAGE gel pictures of full-length Shc, Shc PTB domain and SH2 domain.
All three recombinant proteins are shown in monomeric state with a good purity after the
purification process.

ITC Experiments
Calorimetric measurements of a full length Shc, PTB domain, and SH2 domain to β 3
phosphopeptides or PtdIns were performed on a low volume Nano ITC (TA Instruments). All
experiments were carried out in a buffer of 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM βmercaptoethanol (unless described otherwise) at 12 or 25 °C with a stirring speed of 250 rpm
to minimize the precipitation of the protein. 300 second time intervals were set between
injections. The concentration of protein samples was determined by UV measurements. The
titrants (β3 phosphopeptides or PtdIns) were prepared in the same buffer by the dilution of
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higher concentration stocks. The concentrations of the protein ranged from 30 μM to 150 μM.
The concentration of protein was examined after each ITC experiment by UV to ensure the
stability of proteins under the test condition. The analysis of the data was done with
NanoAnalyze Software (TA Instruments) suite using an “independent” model. In all cases, a
stoichiometry of 1 ± 0.15 was revealed for the interaction between protein and β3
phosphopeptides/PtdIns.
15N-HSQC

Titration by NMR

15

N-labelled recombinant proteins were overexpressed in M9 medium supplemented

with 15NH4Cl as the sole nitrogen source. The same purification procedures as described above
were followed. NMR samples of 100-200 µM were prepared in a buffer of 50 mM Tris, pH 7.5,
100 mM NaCl, 5 mM β-mercaptoethanol, 7% D2O, 1 mM 4,4-dimethyl-4-silapentane-1-sulfonic
acid as the internal standard.

15

N-HSQC titration experiments were performed on a

Varian/Agilent Inova 600 MHz spectrometer equipped with inverse-triple resonance cryo-probe
at 35 °C. All spectra were processed with NMRPipe (66) and analyzed in CCPNmr Analysis
software suite (67).
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Chapter 5 Vγ9Vδ2 T cells in the Immune System

Overview of the Immune System in Humans

The immune system detects and fights against pathogens including foreign proteins,
virus, bacteria and even cancer cells. The immune system in many species including humans
can be classified into two sub-systems (Figure 19), non-specific or innate immune system, and
specific or adaptive immune system. The innate immune system recognizes the conserved
features of pathogens which successfully enters the organisms and is quickly activated to
attack the invaders; however, it defends pathogens in a generic way and cannot develop
immunological memory. Another function the innate immune system has is to work as APCs
to activate the adaptive immune system. The adaptive immune system, on the other hand, is
able creates immunological memory after the initial exposure to the pathogens and develops
long-lasting immunity.

Figure 19. The innate and adaptive immune response. Figure taken from Alberts B,
Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science;
2002. Figure 24-1, Innate and adaptive immune responses.
The adaptive immune system produces both humoral (antibody-mediated) response
and cell-mediated response (Figure 20). In humoral immunity, extracellular antigens are
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targeted and antibodies are secreted to destroy the antigens. Cell-mediated immunity is
triggered when intracellular infections occur and does not involve antibodies.

Figure 20. Cell-mediated immune response and antibody response. Figure taken from
Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York:
Garland Science; 2002. Lymphocytes and the Cellular Basis of Adaptive Immunity.

Lymphocytes: B Cells and T Cells

Lymphocytes are a type of white blood cells in immune system and responsible for
adaptive immune responses to infections and other foreign substances, and host defense
against diseases. There are two primary types of lymphocytes, B cells and T cells. B cells are
largely involved in the humoral immune response (Figure 21). The activation of B cells is
triggered by antigens usually in a T cell-dependent manner. B cells then proliferate and
differentiate in to plasma cells producing an antibody targeting the specific antigen the B cell
is exposed to. In addition, B cells can internalize and process antigens and then present the
peptides to T cells using MHC II molecules. Thus B cells belong to the family of professional
APCs.
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Figure 21. Humoral immune response by B cells activated in presence of helper CD4+ T
cells. Figure taken from Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The
Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001.
Chapter 9, The Humoral Immune Response.
T cells play a central role in the cell-mediated immune response. In the lineage of T
cells, T cells expressing a αβ TCR, αβ T cells, constitute the majority of T cells in humans. αβ
T cells are among the best studied T cell lineage and often considered as “conventional”. αβ
T cells can be further categorized as either “helper CD4+ T cells”, which recognize antigens
via MHC II (Figure 22) and help to activate the other immune cells (such B cells, Figure 23) by
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releasing cytokines, or “cytoxic CD8+ T cells”, which recognize antigens via MHC I and directly
kill target cells including cancerous, infected and damaged cells (Figure 22). The recognition
between αβ TCR and antigen peptides has low binding affinity and specificity.

Figure 22. Helper CD4+ T cells vs. cytoxic CD8+ T cells in antigen recognition. Figure
take from reference (68).
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Figure 23. Comparison of the signals required to activate a helper T cell and a B cell.
Figure taken from Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition.
New York: Garland Science; 2002. Helper T Cells and Lymphocyte Activation.
On the other hand, T cells expressing a γδ TCR, γδ T cells, comprising only a small
percentage of the circulating T cells, are far less understood. The antigenic specificities and
functional features of γδ T cells are being investigated actively and extensively (69-73). γδ T
cells show innate cell-like features allowing its early activation induced by conserved stressinduced ligands. In addition, γδ T cells are capable of producing cytokines rapidly in case of
tissue stress (74). Most of the molecular mechanism of the activation of γδ T cells remains
enigmatic. Nonetheless, γδ T cells garner increasing interest due to its killer cell-like cytotoxic
activity against cancer cells (74).

Vγ9Vδ2 T Cells

In humans and non-human primates, Vγ9Vδ2 T cells represents the majority of γδ T
cells circulating in blood and account for between 1% and 10% of total blood T cells (69).
Vγ9Vδ2 T cells express a TCR containing a Vδ2 chain paired with a Vγ9 chain. Both Vδ2 and
Vγ9 genes are evolutionarily conserved in primates (75) and such a pairing only exists in
humans and primates (76). The Vγ9Vδ2 T cells can rapidly acquire characteristics of
professional APCs after activation (77). Vγ9Vδ2 T cells exhibit anti-microbial and anti-tumor
properties (73), which make them a promising target for immunotherapies for a variety of
diseases.
Structurally, Vγ9Vδ2 TCR has a smaller angle between Vγ and Cγ domains compared
to αβ TCR (110° vs. 147°, Figure 24). The V domains of Vγ9Vδ2 TCR are generally similar to
αβ TCR; however the C domains are remarkably different, which may provide the molecular
basis of a distinct recognition/signaling mechanism compared to αβ TCR.
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Figure 24. αβ TCR vs. Vγ9Vδ2 TCR. Figure modified from reference (78).

Activation of Vγ9Vδ2 T Cells by Phosphoantigens

Distinct from αβ T cells, γδ T cells can be activated in a MHC-independent manner. In
humans, the activation of Vγ9Vδ2 T cells can be triggered by non-peptide phosphorouscontaining small molecules also known as phosphoantigens. The Vγ9Vδ2 T cells are sensitive
to

the

di-phosphorylated

isoprenoid

intermediates

(E)-4-hydroxy-3-methyl-but-2-enyl

pyrophosphate (HMBPP), which is produced by bacterial in the non-mevalonate pathway
(Figure 25), leading to Vγ9Vδ2 T cell anti-microbial functions. Cancer cells can produce
another natural phosphoantigen, isopentenyl pyrophosphate (IPP), from the human
mevalonate pathway (Figure 25). IPP can also activate Vγ9Vδ2 T cells resulting in rapid
expansion and cytotoxicity against cancer cells.
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Figure 25. Isoprenoid biosynthesis in bacterial and human. Figure taken from reference
(79).
Novel γδ T cells-based immunotherapeutical approaches have been proved promising
in the treatment for a variety of diseases including cancers (73, 80). Here we summarized
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briefly the rationale of Vγ9Vδ2 T cells cells-based cancer immunotherapies (73, 80-83). First,
Vγ9Vδ2 T cells are capable of infiltrating tumors and accumulating at tumor sites. Secondly,
Vγ9Vδ2 T cells exhibit a potent cytotoxicity against a broad range of malignancies while
sparing normal cells by secreting cytokines. Thirdly, the activation of γδ T cells can be triggered
by

exogenous

supply

of

phosphoantigens

or

bioaccumulation

of

endogenous

phosphoantigens (80).
A number of selective agonists of Vγ9Vδ2 T cells have been developed and are being
tested under clinical trials for a variety of malignancies. As reviewed in reference (79),
phosphoantigens to activate Vγ9Vδ2 T cells can be classified into two direct and indirect
categories. Direct phosphoantigens, such as HMBPP and IPP and synthetic analogs from
them, are able to directly bind to BTN3A1, a critical positive regulator in Vγ9Vδ2 T cell
activation. In contrast, the mentality of using indirect phosphoantigens to activate Vγ9Vδ2 T
cells is largely based on inhibition the human isoprenoid metabolism, particularly farnesyl
diphosphate synthase, to elevate the level of the direct phosphoantigen of IPP (Figure 25).
Some FDA-approved bisphosphonates for the treatment of other diseases were found
to have anti-tumor activities (84), which were believed to be associated with their antagonistic
effect of Vγ9Vδ2 T cells. Zoledronate (Figure 26), a third-generation bisphosphonate drugs
used for osteolysis and high blood calcium levels, is an effective farnesyl diphosphate synthase
inhibitor (79). BrHPP, a synthetic analog of HMBPP, was found to trigger Vγ9Vδ2 T cell
activation at nanomolar concentrations with minimal unspecific binding at micromolar
concentrations

(85).

Zoledronate

and

BrHPP,

representing

indirect

and

direct

phosphoantigens, respectively, have been evaluated in a handful clinical studies for a variety
of cancers (79, 80). Although treatment Zoledronate or BrHPP with IL-2 have been shown to
have good safety and some efficacy for certain malignancies, mixed results indicate
phosphoantigens may have different stimulation patterns. Thus a better understanding of the
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underlying molecular mechanism how phosphoantigens cause activation of Vγ9Vδ2 T cells is
undoubtedly crucial for future studies on phosphoantigens in Vγ9Vδ2 T cell-based
immunotherapies.

Figure 26. Structure of zoledronate

Figure 27. Structure of BrHPP
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BTN3A1 in Activation of Vγ9Vδ2 T Cells

BTN3A1, the butyrophilin subfamily 3 member A1, is a B7 immunoglobulin superfamily
protein. By far, 13 members of the butyrophilin family have been identified (86). Enriched
content of butyrophilins was detected in milk lipid globules. Thus butyrophilins were originally
believed to be important only in lactation and milk production (87). Due to their structural
features of B7 superfmily of co-stimulatory molecules (Figure 28), and their expression in
immune cells and cells closely interacting with immune cells, butyrophilines have been studied
actively to explore their immunological functions as nicely reviewed in a recent reference (86).
B7 family members feature a protein architecture of extrcellular IgV and IgC domains,
a transmembrane region and a short cytoplasmic tail (Figure 28). Butyrophilin and butyrophilinlike family members retain the same IgV-IgC extracellular structure but, distinct from other B7
family members, comprise a B30.2 (PRY/SPRY) intracellular domain following the
transmembrane region (Figure 28).
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Figure 28. Protein architecture of B7 family and butyrophilin superfamilies. Figure taken
from (86).
Recently, BTN3A1 has been identified as the binding partners for direct
phosphoantigens (such as HMBPP and IPP), establishing its significance in Vγ9Vδ2 T cell
activation. The fact that the direct interaction between BTN3A1 and phosphoantigens leads to
the following Vγ9Vδ2 T cell activation has been recognized. Models of intracellular and
extracellular binding of BTN3A1 to phosphoantigens have been proposed by different groups.
We used a phosphoantigen prodrug approach to demonstrate this strategy has superior
potency in Vγ9Vδ2 T cell activation compared to other current phosphoantigens clinically used.
Furthermore, our biophysical data from NMR and ITC undoubtedly suggests an intracellular
binding of BTN3A1 to phosphoantigens. With those findings, the underlying molecular
mechanisms of phosphoantigen-induced Vγ9Vδ2 T cell activation has been advanced and a
prodrug approach provides new possibilities for development of phosphoantigens for Vγ9Vδ2
T cell-based immunotherapies.
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Chapter 6 Do Phosphoantigens Bind to the Extracellular IgV Domain of
BTN3A1?

Critical review on reference (88)

The Extracellular Binding Model of IgV-Phosphoantigen

During the course of these studies, two groups reported binding of phosphoantigens to
BTN3A1 via conflicting mechanisms, extracellular vs. intracellular. Initially, De Libero and
colleagues demonstrated extracellular binding (88), whereas a recent paper by Adams clearly
showed intracellular binding (89). The exact binding site on BTN3A1 for phosphoantigens is a
matter of debate. However, our biological and biophysical studies clearly suggest an
intracellular interaction between BTN3A1 and phosphoantigens as also confirmed by other
independent studies (Chapter 7).
De Libero and colleagues purposed a model where the extracellular IgV domain of
BTN3A1 binds phosphoantigens suggesting BTN3A1 functions as the antigen-presenting
molecule for the activation of Vγ9Vδ2 T cells. In this study, biophysical evidence showing direct
extracellular binding of BTN3A1 IgV domain to phosphoantigens are mainly from three
methods: X-ray Crystallization, Mass spectroscopy and SPR analysis. Here is the argument
that the results presented in the paper may be deceptive leading to the extracellular model.

Crystal Structures of IgV Complexed with Phosphoantigens

Two main structures, IgV-IPP (PDB entry: 4JKW) and IgV-HMBPP (PDB entry: 4K55),
were determined by X-ray with a resolution of 2.0 Å. The protein did resemble an
immunoglobulin V domain structure. However, after a closer investigation on the molecular
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details of the binding site, the electron density map shows an almost identical “donut” shape
for both ligands, IPP and HMBPP. Both IPP and HMBPP have a structure distinct from a
circular shape (Figure 32). Indeed, both ligands can only occupy half of the “donut” leaving a
vacancy for the other half (Figure 29). This strongly suggests a poor fitting of the
phosphoantigen onto the electron density map and leads to the question of what the ligand is
exactly in the structures. Our hypothesis was that PEG molecules, the co-precipitant regent
used for the crystallization, bind to the Lys39 residue of IgV domain. Another structure from
PDB clearly shows a PEG molecule can adopt a circular shape during crystallization and wrap
itself around the side-chain of a Lys residue (Figure 30) (90, 91). Our speculations were
confirmed by another independent research group (Figure 31) (89).

Figure 29. Electron density of BTN3A1 IgV-phosphoantigen structures constructed from
PDB entries: 4JKW and 4K55 showing a poor fitting for both IPP and HMBPP
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Figure 30. PEG molecules in a circular shape with a Lysine residue in the center (PDB
entry: 3FFR). Figure taken from Crystal structure of phosphoserine aminotransferase SerC
(EC 2.6.1.52) (YP_677612.1) from CYTOPHAGA HUTCHINSONII ATCC 33406 at 1.75 A
resolution (To be published).
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Figure 31. PEG molecules showing a better fitting than HMBPP (PDB entry: 4K55) and
IPP (PDB entry: 4JKW). Figure taken from reference (89).

Mass Spectroscopy and SPR Analysis of the IgV-Phosphoantigen Interaction

In the investigation of the direct IgV-phosphoantigen interaction claimed by De Libero
and colleagues (88), IPP and GDP (as a negative control) were chosen to perform the Mass
Spectroscopy study. Considering stronger affinity of HMBPP, it is surprising to see HMBPP
was not tested for reasons not explicitly reported. The interaction between IgV and IPP with
1:1 stoichiometry was confirmed in an iso-trap mass spectrometer with electrospray ionization
as the de-convoluted spectrum of IgV-IPP showed an increase of 244 Da which is close to the
molecular mass of IPP, 246 Da. Considering that the Kd is in low-micromolar range, it is
debatable if the non-covalently bound IPP can survive the ionization during the experiment.
Mass Spectroscopy may not be the perfect tool for this type of interactions as extreme cautions
need to be taken in the search for the optimal conditions (92). In addition, few Mass
Spectroscopy data other than the de-convoluted spectra was provided to support the result.
The kinetics of IgV-IPP and IgV-HMBPP interactions were assessed using SPR by De
Libero and colleagues (88). A stronger binding was suggested for HMBPP than IPP, with
association rate constants of 76.6 M-1s-1, 746.9 M-1s-1 and dissociation rate constants of 5.35
× 10-3 s-1, 2.28 × 10-3 s-1 for IPP and HMBPP, respectively. The equilibrium binding constants
(Kd) were calculated to be 69.6 µM for IPP and 3.06 µM for HMBPP. However, one of
disadvantages of SPR is that it cannot effectively distinguish specific from non-specific
bindings. Additionally, the SPR studies of ligand bindings of low molecular weight usually do
not have a good sensitivity (93-95). Thus we argue that the confirmation of a specific and direct
interaction between the extracellular IgV domain and phosphoantigens by SPR lacks credibility.
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In summary, the extracellular binding presented by De Libero and colleagues is unclear
as all of three main biophysical experiments had noticeable flaws. Almost at the same time,
Adams group and our group published two independent studies. Both studies undoubtedly
suggest an intracellular binding of BTN3A1 to phosphoantigens. Confirmed by other following
independent studies (96), the intracellular binding model of BTN3A1 to phosphoantigens has
been widely acknowledged. A better understanding of the interaction between BTN3A1 and
phosphoantigens sets the right course for future studies on phosphoantigens in Vγ9Vδ2 T cell
activation, and lays the groundwork for development of next-generation Vγ9Vδ2 T cell-based
immunotherapies.
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Chapter 7 Intracellular Binding of BTN3A1 to Phosphoantigens

Based on Hsiao, C.H.C., Lin, X., Barney, R.J., Shippy, R.R., Li, J., Vinogradova, O., Wiemer,
D.F. and Wiemer, A.J., 2014. Synthesis of a phosphoantigen prodrug that potently activates
Vγ9Vδ2 T-lymphocytes. Chemistry & biology, 21(8), pp.945-954.

A POM-protected Phosphoantigen is Highly Potent in Vγ9Vδ2 Stimulation.

Drugs of phosphates and phosphonates are being explored exceedingly in anticancer
and antiviral therapy. Prodrugs of phosphates and phosphonates have significantly improved
bioavailability, membrane permeability and plasma stability (97). Small and highly charged
molecules (such as phosphoantigens) exhibit low cellular concentration due to the need for
endocytic uptake. Prodrugs (such as POM-protected molecules) mask the negative charged
groups ensuring a passive diffusion across the cell membrane. After the cellular entry, the
POM-protecting groups are removed by cellular esterases generating the functional
phosphoantigens.
Compound 1a, a modest phosphoantigen (98), was chosen for our prodrug strategy
due to its better chemical stability against phosphatase metabolism. A series of protected
compounds (Figure 32) were synthesized and tested in human peripheral blood Vγ9Vδ2 T cell
stimulation and the cell-based assay provided very exciting results (Table 7).
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Figure 32. Chemical structures of phosphoantigens used in the study

Compound

EC50 (μM)

Fold
difference
from HMBPP

Fold
difference
from 1a

IC50
(μM)

Selectivity
index

HMBPP

0.00051

1.0

NA

0.50

980

IPP

36

71000

NA

ND

ND

Risedronate

1.6

3100

NA

61

38

1a

4.0

7800

1

ND

ND

1b

0.0054

10

740

0.60

110

1c

0.50

980

8

8.6

17

1d

> 10

> 19000

NA

ND

ND

NA, not applicable; ND, not determined.
Table 7. Activity of compounds for expansion of Vγ9Vδ2 T Cells from human peripheral
blood mononuclear cells and inhibition of cell viability
Compound 1a showed a moderate potency in Vγ9Vδ2 T cell stimulation (Table 7). The
dimethyl phosphonate, compound 1d, was predicted to be inactive for its metabolism stability
(99) and indeed was not able to stimulate Vγ9Vδ2 T cell (Table 7). Compound 1c is compound
1d with a labile POM group replacing one of the two methyl groups (Figure 32). The
introduction of a POM group was able to restore the stimulatory effect and was more potent
than compound 1a (Table 7). The double POM-protected or bis-POM phosphoantigen,
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compound 1d, exhibited the highest potency among compounds 1a-1d and provided an EC50
of 0.0054 µM (Table 7). The results proved the concept of using a bis-POM phosphoantigen
to achieve Vγ9Vδ2 T cell stimulation.
HMBPP, a potent direct phosphoantigen, showed an EC50 of 0.00051 µM which is the
strongest in all the phosphoantigens tested. However, due to the highly-charged negative
groups, HMBPP suffers from poor pharmacokinetic properties, rapid plasma clearance and
low membrane permeability (100). Compared to HMBPP, our bis-POM phosphoantigens,
compound 1b, showed a much higher potency in our 2-hr Vγ9Vδ2 T cell stimulation (Figure
33D). The fast stimulatory effect is believed to be a result from the enhanced uptake of
compound 1b. Although less potent than HMBPP, compound 1b was still able to stimulate
Vγ9Vδ2 T cell at low nanomolar concentrations.

Figure 33. Bis-POM prodrug compound 1b functions as a direct phosphoantigen with
elevated potency relative to compound 1a and HMBPP. * indicates statistical significance.
Risedronate and other indirect phosphoantigens are known to activate Vγ9Vδ2 T cell
by inhibiting farnesyl diphosphate synthase in the human isoprenoid metabolism (Figure 25).
The resulted cellular accumulation of IPP, the natural direct antigen, induces stimulation of
64

Intracellular Binding of BTN3A1 to Phosphoantigens
Vγ9Vδ2 T cells. To prove that our bis-POM compound 1b works as a direct phosphoantigen,
compound 1b was compared with Risedronate in Vγ9Vδ2 T cell stimulation with treatment of
lovastatin (Figure 33C). Lovastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase
upstream of farnesyl diphosphate synthase, and counters the induced accumulation of IPP by
indirect phosphoantigens such as Risedronate. The stimulated Vγ9Vδ2 T cell proliferation by
compound 1b was not decreased by treatment of lovastatin, which notably abated the
stimulatory effect of Risedronate. This study, and the biophysical evidence for a direct
intracellular between BTN3A1 and compound 1a, prove our hypothesis that our bis-POM
compound 1b is a direct-acting phosphoantigen.

The BTN3A1 PRY/SPRY (B30.2) Domain Directly Binds Phosphoantigens.

It recently was reported that BTN3A1 is required for phosphoantigen detection by
Vγ9Vδ2 T cells (88, 101, 102). However, the exact region of BTN3A1 where phosphoantigens
bind is a matter of debate (88, 101). Based on the 740x increase in activity of the bis-POM
prodrug, we hypothesized that intracellular binding occurs, which is in contrast to the model of
extracellular binding to the immunoglobulin-like V (IgV) (88). To determine whether the
BTN3A1-antigen complex forms intracellularly or extracellularly, we expressed the
recombinant extracellular IgV domain, the intracellular PRY/SPRY (B30.2) domain, and the full
intracellular domain (BFI) and purified the soluble proteins. First, we verified the conformations
of the constructs by NMR, and, according to the nicely dispersed 1H-15NHeteronuclear Single
Quantum Correlation (HSQC) spectra, all the recombinant proteins are well folded and remain
in monomeric state. Most of the amide resonance frequencies for PRY/SPRY domain
overlapped with the peaks in the spectra for BFI (presented overlaid in Figure 34). This
suggests the structure of PRY/SPRY domain in isolated form and in the context of the full-
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length protein remains the same and that the 68-residue membrane proximal region does not
interact with the PRY/SPRY domain intramolecularly.

Figure 34. Evidence for the absence of major 18 intramolecular interactions between the
68-residue membrane-proximal region and PRY/SPRY domain: HSQC spectra of BFI
(black) and PRY/SPRY (gray)
We performed ITC to measure the interactions between these three BTN3A1
constructs and HMBPP (Figure 35A). While no binding was observed with the extracellular
BTN3A1 IgV domain, both the intracellular PRY/SPRY (B30.2) domain and the BFI domain
showed strong binding with dissociation constants (Kd) of 1.61 μM and 1.54 μM, respectively.
The interaction of HMBPP with BTN3A1 was enthalpy-driven with an unfavorable entropy
change. HMBPP binding to the full intracellular domain (ΔH = -51.9 kJ/mol and TΔS = -18.7
kJ/mol) and the PRY/SPRY domain (ΔH = -49.4 kJ/mol and TΔS = -16.4 kJ/mol) shares very
similar enthalpy and entropy terms, which reveals the binding site on BTN3A1 for
phosphoantigens is enclosed in the PRY/SPRY domain (Table 8). 1H-15N HSQC titrations of
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HMBPP agreed with the ITC results. While there were no chemical shift perturbations in the
spectrum for the IgV domain upon HMBPP titration (Figure 36) the effects from HMBPP on the
spectra of BFI and PRY/SPRY were very pronounced. HMBPP-concentration-dependent
chemical shift perturbations were observed in the spectra for both BFI (Figure 37A) and the
PRY/SPRY domain (Figure 37B) and reached saturation at an HMBPP:protein ratio of 3:1.
Combining ITC and NMR data, we have demonstrated that HMBPP interacts with BTN3A1 at
its intracellular domain at 1:1 ratio and is likely capable of inducing significant conformational
rearrangements in the intracellular domain of BTN3A1.

Figure 35. Binding of HMBPP and Compound 1a to the Intracellular Domain of BTN3A1.
(A) Isothermal titration calorimetry plots for the interaction of HMBPP with the extracellular IgV
domain (gray line/dots), the full intracellular domain (BFI) (black line/dots), or the isolated
PRY/SPRY (B30.2) domain (red line/dots). (B) Isothermal titration calorimetry plots for the
interaction of the full intracellular domain (BFI) of BTN3A1 with HMBPP in the absence of
compound 1a (red line/dots), or the presence of 10x compound 1a (gray line/dots), or 100x
compound 1a (blue line/dots).
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ΔH
kJ/mol

Protein or protein-ligand complex Ligand

Kd
µM

IgV

No binding

PRY/SPRY

HMBPP

BFI
1:10
BFI + Compound 1a

ΔG
kJ/mol

1.61

-49.4

-16.4

-33.0

1.54

-51.9

-18.7

-33.2

1.70

-49.1

-16.2

-32.9

1.26

-28.3

5.33

-33.6

1.15

-46.6

-12.7

-33.9

2.55

-38.7

-6.78

-31.9

1.95

-47.1

-14.5

-32.6

HMBPP
1:100
1:10

BFI + IPP

HMBPP
1:100

BFI

TΔS
kJ/mol

C-HDMAPP

Table 8. Summary of the thermodynamic data derived from the ITC measurements using
different ligands

Figure 36. Evidence for the absence of interaction between HMBPP and the extracellular
IgV domain of BTN3A1. HSQC of spectra of free IgV domain (black), IgV + HMBPP at 1:1
protein-to-compound ratio (blue) and IgV + HMBPP at 1:3 protein-to-compound ratio (red). The
three spectra overlap perfectly indicating no interaction between HMBPP and the IgV domain.
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Figure 37. 1H-15N HSQC titration of HMBPP into the full-length intracellular domain and
the PRY/SPRY domain of BTN3A1. Compared to the PRY/SPRY domain, the full-length
intracellular domain of BTN3A1 (BFI) includes an additional membrane-proximal region of 68
residues at the N-terminus, which is demonstrated to be involved in the interaction with HMBPP
and to undergo significant structural changes upon binding. (A) Chemical shift perturbations
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for the interaction of HMBPP and BFI at ratios of 0:1 (black), 1:1 (blue), 3:1 (red). (B) Chemical
shift perturbations for the interaction of HMBPP and the PRY/SPRY domain at ratios of 0:1
(gray), 1:1 (orange), 3:1 (green). (C) Evidence for the involvement of the 68-residues
membrane-proximal region in interaction with HMBPP: HSQC spectra of the free BFI (black),
BFI + HMBPP at 1:3 ratio (red) and PRY/SPRY + HMBPP at 1:3 ratio (green). Peaks which
belong to the 68-residue membrane-proximal region are absent in the spectrum of PRY/SPRY
domain. Arrows indicate the peaks corresponding to the amides from this region that have
showed remarkable shifts upon binding to HMBPP, thus suggesting significant structural
rearrangements.
To determine whether binding was specific to HMBPP or a general property of
phosphoantigens, we also tested whether another potent phosphoantigen, C-HDMAPP, could
bind to internal domain (Figure 38). C-HDMAPP is a phosphonate analog of HBMPP (98).
Interestingly, C-HDMAPP exhibited similar energetics relative to HMBPP when binding to the
PRY/SPRY domain (Kd = 1.95 μM, ΔH = -47.1 kJ/mol, TΔS = -14.5 kJ/mol). The data reveals
that both HMBPP and C-HDMAPP bind with high affinity to the intracellular PRY/SPRY (B30.2)
domain but not the extracellular V domain. C-HDMAPP has a slightly weaker interaction which
is consistent with its activity in cellular assays (98). Therefore, we have demonstrated that two
different phosphoantigens bind strongly to the intracellular domain of BTN3A1.
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Figure 38. Binding of C-HDMAPP to the BTN3A1 full intracellular domain
Because IPP also acts as a direct phosphoantigen in cellular assays, we tested its
ability to interact with BTN3A1. However, we were unable to measure directly the binding of
IPP to BTN3A1 by ITC. This is perhaps not surprising, given that the activity in cellular assays
is approximately 71,000 fold less for IPP relative to HMBPP (Table 8) making the projected
dissociation constant well outside of the detection limit of ITC. Therefore, we performed a
competition ITC study to determine whether increasing concentrations of IPP would affect the
binding of HMBPP to BTN3A1 (Figure 39). IPP dose-dependently decreased the favorable
enthalpy of HMBPP binding from a ΔH of -51.9 kJ/mol to -47.7 kJ/mol and -38.7 kJ/mol at
IPP:BTN3A1 ratios of 10:1 and 100:1, respectively (Table 8). IPP also dose-dependently made
more favorable the TΔS term of HMBPP binding, changing it from -18.7 kJ/mol to -12.7 kJ/mol
and -6.78 kJ/mol at IPP:BTN3A1 ratios of 10:1 and 100:1 respectively. Taken together, the
data show that IPP binds to BTN3A1 with a much weaker affinity compared to HMBPP and
that both compounds compete for the same binding site within the PRY/SPRY domain.
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Figure 39. Binding of HMBPP to the BTN3A1 full intracellular domain in the presence of
IPP (no IPP, red line; IPP:BTN3A1=10:1, gray line; IPP:BTN3A1=100:1, blue line)
Because compound 1b is expected to undergo metabolic cleavage, resulting in
accumulation of compound 1a, we examined the binding affinity between compound 1a and
the BTN3A1 PRY/SPRY domain. Like IPP, the binding affinity of 1a was undetectable in ITC
when using compound 1a as the sole ligand, as we had purposely chosen a weak
phosphoantigen for the prodrug studies. However, as expected, compound 1a had a markedly
stronger effect on the HMBPP binding to the PRY/SPRY domain relative to IPP (Figure 35).
Like IPP, compound 1a dose-dependently decreased the favorable enthalpy of HMBPP
binding to BTN3A1 (Table 8). These effects also were measured at 1a:BTN3A1 ratios of
0:1(ΔH of -51.9 kJ/mol), 10:1 (-49.1 kJ/mol) and 100:1 (-28.5 kJ/mol). Compound 1a also dosedependently made more favorable the TΔS term of HMBPP binding at IPP:BTN3A1 ratios of
10:1 (-16.2 kJ/mol) and 100:1 (+5.19 kJ/mol). These data fit well with the cellular data in that
1a is a more potent phosphoantigen relative to IPP and would be expected to have a stronger
effect. Perhaps surprisingly, the entropy term became positive at the highest concentration of
1a. This finding demonstrates that the prenyl alcohol and/or the olefin position play a more
important role in the phosphoantigen-BTN3A1 interaction as compared to the distal phosphate
group. Thus, according to ITC data, compound 1a may induce conformational changes in the
intracellular domain of BTN3A1 similar to the ones induced by the stronger interaction with
HMBPP and absent in the interface with IPP.
To confirm that IPP and compound 1a do have direct interactions with the intracellular
domain of BTN3A1, 1H-15N HSQC titrations of IPP and compound 1a into BFI were performed
at ligand:protein molar ratios of 0:1, 10:1 and 100:1. Both IPP (Figure 40A) and compound 1a
(Figure 40B) showed concentration-dependent perturbations in the spectra. These two sets of
titration data demonstrate that both IPP and compound 1a bind to BFI at a similar binding site
with only a limited number of distinct differences in amide chemical shift perturbations between
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the two. In addition, the spectrum of compound 1a, but not IPP, shows several chemical shift
perturbations identical to the ones observed in the titration of HMBPP (marked by arrows on
Figure 40C). Thus our NMR and ITC results are mutually consistent and suggest that binding
sites for IPP and compound 1a on the PRY/SPRY domain are quite similar, although each
compound is also involved in unique interactions with BTN3A1.
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Figure 40. 1H-15N HSQC titration of IPP and compound 1a into the full-length intracellular
domain of BTN3A1 (BFI). (A) Chemical shift perturbations for the interaction of IPP and BFI
at ratios of 0:1 (black), 10:1 (blue), 100:1 (red). (B) Chemical shift perturbations for the
interaction of compound 1a and BFI at ratios of 0:1 (gray), 10:1 (orange), 100:1 (green). (C)
Comparison of BFI chemical shifts and in the presence of IPP (red) and compound 1a (green)
at 100:1 compound-to-protein ratio (the spectrum of BFI in free form shown in black). Arrows
indicate chemical shift perturbations found for compound 1a, but not IPP, which are identical
to the ones observed in the titration of HMBPP.

The Intracellular Domain of BTN3A1 Undergoes Conformational Changes after
Binding to Phosphoantigens.

Adams group was able to determine the structures of BTN3A1 B30.2 domain in free
and bound forms with a resolution of 1.4 Å (89). The structures revealed a basic pocket for
phosphoantigen binding and mutations of key residues from positive to negative completely
ablated phosphoantigen binding. The phosphoantigen used for crystallization structural
determination was cHDMAPP, which showed a similar thermodynamic profile as HMBPP
(Table 8) in our ITC experiments, which is also consistent with their results.
Surprisingly, the free B30.2 domain and the B30.2-cHDMAPP complex are almost
identical structurally as the phosphoantigen was not able to induce any noticeable
conformational changes in BTN3A1 (Figure 41). This leads to a question: what is the molecular
mechanism connecting the phosphoantigen binding to the downstream signaling then to the
eventual activation of Vγ9Vδ2 T cells?
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Figure 41. Structural comparison between free BTN3A1 B30.2 domain (gray, PDB entry:
4N7I) and B30.2-cHDMAPP complex (green, PDB entry: 4N7U)
The unobserved structural changes in B30.2 domain may be explained by the BTN3A1
construct used in the study. Compared to our BFI construct, the B30.2 domain is truncated at
the N-terminus and lacks the 68-residue juxtamembrane (JM) region. Our 1H-15N HSQC
titration data indicate the involvement of the 68-residue JM region in interactions with
phosphoantigens (Figure 37). This evidence indirectly proves the significance of the JM region
in the probable structural rearrangements of intracellular BTN3A1. As the JM region may be
the harbor for cellular binding partners such as periplakin (96), biologically and functionally, it
is reasonable to speculate the JM region can be switched from “inactive” form to “active” form
upon binding of phosphoantigens. Another possibility is that the JM region interacts with the
cell membrane, which enables BTN3A1 to have an “inside-out” signaling like integrins. In this
scenario, the intracellular binding of BTN3A1 to phosphoantigens causes a change in binding

76

Intracellular Binding of BTN3A1 to Phosphoantigens
affinity of the extracellular domain to its unknown counter-partners. It is plausible since the
ectodomain of BTN3A1 seems to dimerize in two different modes, IgC-to-IgC and IgV-to-IgC
(103).
To further investigate the potential structural changes in intracellular BTN3A1
especially the JM region, we performed SAXS analysis on BFI in absence and presence of
HMBPP. Our initial results did suggest changes in the overall shape of BFI. The shape of BFI
can be viewed as a body part and a head part connected by a short neck region. We suspect
the body part encompasses the B30.2 domain due to size similarity in comparison to structure
determined by X-ray. (89). We also believe the JM region forms the head and neck and extends
to the body part. The most pronounced change in shape upon HMBPP binding occurs in the
neck region, where a narrowing is observed. In addition, there are other distinctions between
the free and bound structures, which are difficult to describe at the moment due to the lowresolution of the models. Overall, the SAXS results are consistent with our hypothesis of
BTN3A1 intracellular conformational changes and warrant further structural investigations of
intracellular BTN3A1, especially the JM region.
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Figure 42. Structures of BFI with (green) and without (gray) HMBPP by SAXS

Discussion

During the course of these studies, two groups reported binding of phosphoantigens to
BTN3A1 via conflicting mechanisms (88, 89). Initially, di Libero and colleagues demonstrated
extracellular binding whereas a recent paper by Adams clearly showed intracellular binding.
Our studies are in strong agreement with those from the Adams lab. In addition to the
calorimetry assay, we also see strong interactions as assessed by NMR spectroscopy. Our
results also demonstrate for the first time the relative contribution of the prenyl alcohol group
and/or olefin position is more important that the second phosphate group, because compound
1a affects the binding of HMBPP to BTN3A1 to a much greater extent than IPP, which lacks
the alcohol functional group. Additionally, we have compared the effects of different antigen
binding on the full intracellular domain and the PRY/SPRY domain by NMR. Our results
indicate that although the binding site for phosphoantigens is localized in PRY/SPRY domain,
the 68-residue membrane proximal region, preceding PRY/SPRY, also undergoes major
structural rearrangement upon binding (Figure 37C). These findings clearly promote a model
in which intracellular binding of phosphoantigens to BTN3A1 induces a conformational change,
which either propagates across the membrane to the extracellular region or promotes an
interaction with another intracellular protein thus allowing new transmembrane complex
formation necessary for recognition by the Vγ9Vδ2 T cell receptor.
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Research Design and Methods

Cloning and Purification of BTN3A1 Constructs
BTN3A1 constructs were purified based on the method that De Libero and colleagues
(88) used for the IgV domain with some modifications. Amplicons were obtained from THP-1
cDNA using the following primers in Table 9.

Construct

Forward Primer

GCT ATC CAT ATG TCA
GCT CAG TTT TCT GTG
GCT ATC CAT ATG CAA
BFI
CAG CAG GAG GAA AAA
GCT ATC CAT ATG GCG
PRY/SPRY
GAT GTG ATT CTG GAT
Table 9. Primers used for BTN3A1 constructs
IgV

Reverse Primer
GCT ATC CTC GAG AAC
CTT CAG CTC CAC CAG
GCT ATC CTC GAG CGC
TGG ACA AAT AGT CAG
GCT ATC CTC GAG CGC
TGG ACA AAT AGT CAG

Each forward primer contained an NdeI site while each reverse primer contained an
XhoI site. Following amplification and digest, sequences were cloned into the NdeI and XhoI
sites in pET21b+, resulting in a 6x His-tagged construct. Each construct was validated by
sequencing using the standard T7 forward and T7 reverse primers. The plasmids were
transformed into BL21(DE) E. coli. The cells were grown in LB broth until OD600 reached 0.6
at which point the overexpression was induced by 1 mM IPTG. Cells were lysed by French
Press and the cell debris was removed by centrifugation at 18,000 rpm at 4 °C. The
supernatant containing the soluble target protein was collected for further purification. The Cterminal His-tag fused protein was purified under native conditions with Ni-NTA resin (QIAGEN)
using the standard protocol followed by a buffer exchange to 50 mM Tris, pH 7.5, 100 mM
NaCl, 5 mM β-mercaptoethanol (BME) in a Superdex-75 column (GE Healthcare) where all
three recombinant proteins showed a proper folding in monomeric state. The overexpression
of the target protein and the purified protein were confirmed by SDS-PAGE and bands of the
expected mass were observed.
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ITC Experiments
Calorimetric measurements of BTN3A1 domains to various compounds were
performed on a low volume Nano ITC (TA Instruments). All experiments were carried out in a
buffer of 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM BME at 25 °C with a stirring speed of 200
rpm to minimize the precipitation of the protein. Each titration consisted of twenty 2.5-µl
injections with 300 second time intervals. The concentrations of protein samples were
determined by UV and the titrant of the compounds were prepared in the same buffer from the
dilution of 10 mM or 100 mM stock. The concentrations of the protein ranged from 30 μM to 60
μM. The concentration of protein was examined after each ITC experiment and a good
solubility (> 85%) of the protein under this condition was shown. The analysis of the data was
done in NanoAnalyze Software (TA Instruments) suite using an “independent” model. In all
cases, a stoichiometry of 1 ± 0.1 was revealed.
15N-HSQC

Titration by NMR

15

N-labelled recombinant proteins were overexpressed in M9 medium supplemented

with

15

NH4Cl as the sole nitrogen source. Same purification procedures as described above

were followed. NMR samples of 100-200 µM were prepared in a buffer of 50 mM Tris, pH 7.5,
100 mM NaCl, 5 mM BME, 7% D2O, 1 mM DSS as the internal standard. 1H-15N Heteronuclear
Single Quantum Correlation (HSQC) titration experiments were performed on Varian Inova
600 MHz spectrometer equipped with inverse-triple resonance cyroprobe at 25 °C. All spectra
were processed with NMRPipe (104) and analyzed in CcpNmr Analysis software suite (67).
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Chapter 8 Conclusions

In summary, the above studies on p52 Shc and BTN3A1 demonstrate how ITC and
NMR can be utilized to characterize protein interactions.
Chapter 1 and Chapter 2 serve as a brief overview of the two biophysical techniques.
Chapter 3 discusses the significance of p52 Shc in MAPK and PI3K/AKT pathways. In
Chapter 4, we presented a study on phospho-Tyrosine(s) vs. phosphatidylinositol binding in
p52 Shc-mediated integrin signaling. p52 Shc has been identified as a primary signaling
partner for the tyrosine(s)-phosphorylated cytoplasmic tails of activated β3 integrins. Inspired
by our recent structure of the Shc PTB domain in complex with a bi-phosphorylated peptide
derived from β3 cytoplasmic tail, we have initiated the investigation of Shc interaction with
phospholipids of the membrane. We are particularly focused on PtdIns and their effects on Shc
mediated integrin signaling in vitro. Here we present thermodynamic profiles and molecular
details of the interactions between Shc, integrin, and PtdIns, all of which have been studied by
ITC and solution NMR methods. A model of p52 Shc interaction with phosphorylated β3 integrin
cytoplasmic tail at the cytosolic face of the plasma membrane is proposed based on these data.
Chapter 5 introduces the importance of the Vγ9Vδ2 T cells in human immune system
and highlights the significance of BTN3A1 in the phosphoantigen-induced Vγ9Vδ2 T cell
activation. Chapter 6 is a discussion why the extracellular binding of BTN3A1 to
phosphoantigens is unlikely. In Chapter 7, we demonstrate high affinity interaction between
phosphoantigens and the intracellular domain of BTN3A1: while the PRY/SPRY (B30.2)
domain forms the binding pocket, perturbations in the JM region were also observed upon this
interaction. In addition, our cell-based assay proves a prodrug approach may represent the
future direction of phosphoantigen development in clinical Vγ9Vδ2 T cell-based
immunotherapies.
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